Andere talen Vigil Neuroscience, Inc.

Aandelen

VIGL

US92673K1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,58 ^USD	-6,86%		-6,18%	-23,67%

17/04	Vigil Neuroscience, Inc. presenteert belangrijke bevindingen van Illuminate & Ignite studies in ALSP op de jaarlijkse bijeenkomst van de American Academy of Neurology in 2024	CI
26/03	VIGIL NEUROSCIENCE, INC. : Wedbush ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	17/04
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	17/04
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
North American Morning Briefing : Markets Steady -2-	26/03
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	20/03
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20/03
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20/03
Vigil Neuroscience, Inc. Announces Executive Changes	20/03
North American Morning Briefing : Stock Futures -2-	19/03
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13/03
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13/03
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	12/03
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	06/03
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29/02
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29/02
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	07/02
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	03/01
North American Morning Briefing : S&P 500 Futures -2-	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vigil Neuroscience, Inc.

Aandelen

VIGL

US92673K1088

Andere talen

Filters